IL273727B2 - Lysyl oxidase inhibitors - Google Patents
Lysyl oxidase inhibitorsInfo
- Publication number
- IL273727B2 IL273727B2 IL273727A IL27372720A IL273727B2 IL 273727 B2 IL273727 B2 IL 273727B2 IL 273727 A IL273727 A IL 273727A IL 27372720 A IL27372720 A IL 27372720A IL 273727 B2 IL273727 B2 IL 273727B2
- Authority
- IL
- Israel
- Prior art keywords
- optionally substituted
- compound
- alkyl
- heteroatoms selected
- membered heterocyclyl
- Prior art date
Links
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 title 1
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 32
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 20
- 125000005842 heteroatom Chemical group 0.000 claims 17
- 229910052760 oxygen Inorganic materials 0.000 claims 17
- 229910052717 sulfur Inorganic materials 0.000 claims 17
- 230000003176 fibrotic effect Effects 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 6
- 102000055008 Matrilin Proteins Human genes 0.000 claims 5
- 108010072582 Matrilin Proteins Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 230000035945 sensitivity Effects 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000004043 responsiveness Effects 0.000 claims 4
- 101000743846 Diplobatis ommata Ras-related protein Rab-10 Proteins 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- -1 C1-haloalkyl Chemical group 0.000 claims 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 229940121922 Lysyl oxidase inhibitor Drugs 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 239000013074 reference sample Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101000620967 Diplobatis ommata Ras-related protein Rab-11B Proteins 0.000 claims 1
- 101001132551 Diplobatis ommata Ras-related protein Rab-8 Proteins 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 102000016304 Origin Recognition Complex Human genes 0.000 claims 1
- 108010067244 Origin Recognition Complex Proteins 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 101100397732 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TPK1 gene Proteins 0.000 claims 1
- 102100021119 Serine protease HTRA1 Human genes 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000001370 mediastinum Anatomy 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 150000002780 morpholines Chemical class 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 101150007570 nra-1 gene Proteins 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000004885 piperazines Chemical class 0.000 claims 1
- 150000003053 piperidines Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000574 retroperitoneal space Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 1
- 150000004886 thiomorpholines Chemical class 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1716871.7A GB201716871D0 (en) | 2017-10-13 | 2017-10-13 | Compounds |
| PCT/GB2018/052934 WO2019073251A1 (en) | 2017-10-13 | 2018-10-12 | INHIBITORS OF LYSYL OXIDASE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL273727A IL273727A (en) | 2020-05-31 |
| IL273727B2 true IL273727B2 (en) | 2023-06-01 |
Family
ID=60419229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273727A IL273727B2 (en) | 2017-10-13 | 2020-03-31 | Lysyl oxidase inhibitors |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11325915B2 (https=) |
| EP (1) | EP3694857A1 (https=) |
| JP (1) | JP7385561B2 (https=) |
| CN (1) | CN111212836B (https=) |
| CA (1) | CA3076566A1 (https=) |
| GB (1) | GB201716871D0 (https=) |
| IL (1) | IL273727B2 (https=) |
| WO (1) | WO2019073251A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201716871D0 (en) | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
| GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| CN112533897B (zh) | 2018-08-03 | 2023-07-14 | 法玛西斯有限公司 | 赖氨酰氧化酶的卤代烯丙胺砜衍生抑制剂及其用途 |
| GB201818750D0 (en) * | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| AU2020317374A1 (en) * | 2019-07-25 | 2022-02-03 | Pharmaxis Ltd. | Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof |
| IL326597A (en) | 2019-10-07 | 2026-04-01 | Contineum Therapeutics Inc | Muscarinic M1 acetylcholine receptor antagonists |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| US12578335B2 (en) | 2020-02-05 | 2026-03-17 | Syntara Limited | Bioprobes for lysyl oxidases and uses thereof |
| US20230310445A1 (en) * | 2020-04-21 | 2023-10-05 | Anovia Biosciences, Inc. | Lox enzyme inhibiting methods and compositions |
| US12233056B2 (en) | 2022-04-06 | 2025-02-25 | Syntara Limited | Lysyl oxidase inhibitors for treating myeloid malignancies |
| CN116763899B (zh) * | 2023-07-17 | 2026-02-24 | 大连医科大学附属第一医院 | Htra1抑制剂在制备治疗胰腺炎-癌转化的药物中的应用 |
| CN119732928B (zh) * | 2024-12-26 | 2026-04-07 | 国家纳米科学中心 | 一种抑制胶原纤维形成的药物分子及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011119345A2 (en) * | 2010-03-25 | 2011-09-29 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2016144846A1 (en) * | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of irak4 activity |
| WO2017003862A1 (en) * | 2015-07-01 | 2017-01-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4992546A (en) | 1987-07-31 | 1991-02-12 | Warner-Lambert Company | Process for preparing 6,8-diazabicyclo[3.2.2]nonane derivatives |
| DE4402933A1 (de) | 1994-02-01 | 1995-08-03 | Kali Chemie Pharma Gmbh | Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel |
| CA2657623A1 (en) * | 2006-07-14 | 2008-01-17 | Merck & Co., Inc. | Bridged diazepan orexin receptor antagonists |
| BRPI0821676A2 (pt) | 2007-12-21 | 2015-06-16 | Astrazeneca Ab | Composto, composição farmacêutica, e, processo para a preparação dos compostos. |
| WO2010028011A1 (en) | 2008-09-05 | 2010-03-11 | Targacept, Inc. | Amides of diazabicyclononanes and uses thereof |
| AU2014348518B2 (en) * | 2013-11-14 | 2019-01-03 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9994570B2 (en) | 2014-11-26 | 2018-06-12 | Merck Sharp & Dohme Corp. | Bridged diazepane orexin receptor antagonists |
| ES2880766T3 (es) | 2016-02-09 | 2021-11-25 | Pharmakea Inc | Inhibidores de quinolinona lisil oxidasa similar al tipo 2 y usos de los mismos |
| JP6849197B2 (ja) | 2016-02-12 | 2021-03-24 | ファーマクシス リミテッド | リジルオキシダーゼのインドールおよびアザインドールハロアリルアミン誘導体阻害剤およびその使用 |
| GB201602934D0 (en) | 2016-02-19 | 2016-04-06 | Cancer Res Inst Royal | Compounds |
| US20210009551A1 (en) | 2016-06-02 | 2021-01-14 | The Regents Of The University Of California | Compounds and methods for treating fibrosis or cancer |
| WO2018048928A1 (en) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Chemical probes of lysyl oxidase-like 2 and uses thereof |
| WO2018048930A1 (en) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
| KR102587178B1 (ko) | 2016-09-07 | 2023-10-06 | 파마케아, 인크. | 리실 옥시다아제-유사 2 억제제의 결정질 형태 및 제조 방법 |
| US20200069648A1 (en) | 2017-03-02 | 2020-03-05 | Pharmaxis Ltd. | Haloallylamine pyrazole derivative inhibitors of lysyl oxidases and uses thereof |
| GB201716871D0 (en) | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
-
2017
- 2017-10-13 GB GBGB1716871.7A patent/GB201716871D0/en not_active Ceased
-
2018
- 2018-10-12 CN CN201880065806.5A patent/CN111212836B/zh active Active
- 2018-10-12 WO PCT/GB2018/052934 patent/WO2019073251A1/en not_active Ceased
- 2018-10-12 EP EP18792450.1A patent/EP3694857A1/en active Pending
- 2018-10-12 US US16/755,739 patent/US11325915B2/en active Active
- 2018-10-12 JP JP2020520592A patent/JP7385561B2/ja active Active
- 2018-10-12 CA CA3076566A patent/CA3076566A1/en active Pending
-
2020
- 2020-03-31 IL IL273727A patent/IL273727B2/en unknown
-
2022
- 2022-04-04 US US17/712,541 patent/US12060360B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011119345A2 (en) * | 2010-03-25 | 2011-09-29 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| WO2016144846A1 (en) * | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of irak4 activity |
| WO2017003862A1 (en) * | 2015-07-01 | 2017-01-05 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| SINGH R ET AL:, A GENERAL AND EFFICIENT SYNTHESIS OF 3,6- DIAZABICYCLO[3.2.1 ]OCTANES, 24 April 2006 (2006-04-24) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111212836B (zh) | 2023-12-15 |
| US20200331922A1 (en) | 2020-10-22 |
| EP3694857A1 (en) | 2020-08-19 |
| GB201716871D0 (en) | 2017-11-29 |
| US12060360B2 (en) | 2024-08-13 |
| US11325915B2 (en) | 2022-05-10 |
| CA3076566A1 (en) | 2019-04-18 |
| US20220289757A1 (en) | 2022-09-15 |
| WO2019073251A1 (en) | 2019-04-18 |
| JP2020536924A (ja) | 2020-12-17 |
| CN111212836A (zh) | 2020-05-29 |
| JP7385561B2 (ja) | 2023-11-22 |
| IL273727A (en) | 2020-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273727B2 (en) | Lysyl oxidase inhibitors | |
| AR122783A2 (es) | Inhibidores de kras g12c y métodos para su uso | |
| Zhou et al. | MicroRNA-340 suppresses osteosarcoma tumor growth and metastasis by directly targeting ROCK1 | |
| WO2020033413A3 (en) | Modulators of ras gtpase | |
| EA201891703A1 (ru) | Соединения бензопиразола и их аналоги | |
| JP2018504418A5 (https=) | ||
| JP2020536924A5 (https=) | ||
| BR112018070163A2 (pt) | compostos de aminopurina substituída, composições e métodos de tratamento | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| BR112021020441A2 (pt) | Derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| EA201590345A1 (ru) | Способы лечения рака с использованием 3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона | |
| EA201391629A1 (ru) | Ингибиторы цсж-1r для лечения опухолей головного мозга | |
| MX2019001132A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
| JP2016505621A5 (https=) | ||
| EA201200472A1 (ru) | Сульфонамиды в качестве ингибиторов белков семейства bcl-2, предназначенные для лечения рака | |
| BR112016029846A2 (pt) | ?composto, composição farmacêutica, métodos para o método para tratamento de um humano, para inibição da atividade de um polipeptídio de fosfatidilinositol 3-quinase e inibição excessiva ou reações imunes destrutivas ou crescimento ou uma proliferação de células de câncer, kit, e, uso de um composto, um sal farmaceuticamente aceitável, isômero, ou uma mistura do mesmo? | |
| JP2017502967A5 (https=) | ||
| BR112016028642A2 (pt) | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. | |
| BR112018001534A2 (pt) | inibidor de isocitrato desidrogenase idh1 r132h mutante | |
| EA201890862A1 (ru) | Ингибиторы плазменного калликреина человека | |
| EA202191619A1 (ru) | Производные (пиридин-2-ил)амина в качестве ингибиторов tgfбета r1 (alk5) для лечения злокачественных новообразований | |
| EP3302488A1 (en) | Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry | |
| US20190134034A1 (en) | Method of Treating Liver Cancer | |
| CO2020004201A2 (es) | Inhibidor del receptor del factor de crecimiento epidérmico |